AIM ImmunoTech rises after Ampligen shows promise in cancer trials

AIM ImmunoTech

11/04/2022 14:02

** Drug developer's shares  AIM.A  rise 12.9% to $1.22
premarket
    ** Co reports positive data from two trials testing its
experimental therapy, Amligen, in different types of cancer
 urn:newsml:reuters.com:*:nGNE1WTxwl  urn:newsml:reuters.com:*:nGNE5tlDn6
    ** Main goal of both trials - early stage study in breast
cancer and mid-stage study in patients with colorectal cancer
that has spread to liver  - were met 
    ** Data from both studies presented at AACR 2022 annual
meeting
    ** Stock up 4.8% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))